Artificial Intelligence (AI)-driven Primary Care company K Health announces today the next phase of its quest to tackle the prevention and care of heart-related conditions.
It has entered into a know-how agreement with Mayo Clinic to collaborate with Mayo Clinic cardiologists Francisco Lopez-Jimenez, M.D., M.S., MBA, Chair of the Division of Preventive Cardiology, and Amir Lerman, M.D., Vice Chair of Research at the Department of Cardiovascular Medicine, on the development of a cardiac clinical AI solution with the intent to prevent premature deaths from heart disease and stroke.
According to the World Health Organization, 80% of cardiovascular deaths can be prevented. Proper risk assessment and oversight are key to reducing the amount of premature deaths.
The goal of the cardiac program is to use proprietary algorithms built by K Health to power advanced AI-ECG (AI-enhanced electrocardiography) technology, risk assessments, and remote patient monitoring to help physicians personalize treatment for conditions such as hypertension and high cholesterol, or prevent them entirely.
Drs. Lopez-Jimenez and Lerman will oversee the development and leverage their real-world insight to evaluate the accuracy and effectiveness.
K Health has licensed de-identified patient data from Mayo Clinic Platform to refine its AI models and develop new algorithms since 2020. The AI models used in this program seek to help physicians predict risk and optimal treatment by accounting for specific factors, such as gender, age, medical history, ethnicity, and more.
“Our first step in reducing avoidable cardiovascular deaths was building a machine learning model to allow all hypertension patients to directly benefit from the Mayo Clinic standard of care,” said Ran Shaul, Co-Founder and Chief Product Officer of K Health. “We’re able to help physicians practice more personalized medicine by giving them instant information on their patients, and the know-how of Dr. Lopez-Jimenez and his team are key to bringing our vision of changing the course of heart disease to life.”
